Vystar Corp (VYST)

[Vandal793]

Bloomberg
Subscribe
Business
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
February 7, 2019, 9:18 AM EST
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in
Hospitals, Healthcare Facilities

* Destroys on first pass more than 99.97% of harmful airborne viruses and
bacteria.
* Inactivates pathogens that cause measles, the common cold, MRSA (staph),
whooping cough, TB, pneumonia and other antibiotic-resistant and viral
infections.

WORCESTER, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Vystar Corp. (OTC: VYST)
is resuming production of the Rx3000™, a hybrid air purifier designed by
biomedical engineers specifically for hospitals. The Rx3000 combines powerful
germicidal ultraviolet (UV) light with a patented 5-stage HEPA filtration
proven in independent EPA- and FDA-certified laboratory testing to destroy on
first pass over 99.97% of airborne viruses, bacteria and other contaminants.
Vystar acquired the assets and patented intellectual property related to the
Rx3000, RxAir™, custom filtration and other UV light air purification
technologies from UV Flu Technologies in 2018 after production had stopped.